Patents Assigned to Valneva
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20210121554
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 29, 2021
    Applicants: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ZIKA VIRUS PURIFICATION
    Publication number: 20210093707
    Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.
    Type: Application
    Filed: July 13, 2020
    Publication date: April 1, 2021
    Applicant: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • METHODS AND COMPOSITION FOR PREVENTING AND/OR TREATING CANCER
    Publication number: 20210085775
    Abstract: Described herein are compositions and methods for treating cancers, such as characterized by chronic inflammation or expression of GM1 ganglioside receptors
    Type: Application
    Filed: September 3, 2018
    Publication date: March 25, 2021
    Applicant: Valneva Sweden AB
    Inventors: Klaus Schwamborn, Tim Wood, Jianguang Ji, Jan Sundquist, Kristina Sundquist
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20210054032
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: August 11, 2020
    Publication date: February 25, 2021
    Applicant: Valneva Austria GmbH
    Inventors: Urban Lundberg, Wolfgang Schüler
  • ZIKA VIRUS VACCINE
    Publication number: 20200384099
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: March 10, 2020
    Publication date: December 10, 2020
    Applicant: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • VIRUS PURIFICATION
    Publication number: 20200368342
    Abstract: Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
    Type: Application
    Filed: April 6, 2020
    Publication date: November 26, 2020
    Applicant: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
    Publication number: 20200360511
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Application
    Filed: January 6, 2020
    Publication date: November 19, 2020
    Applicant: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Heindl-Wruss, Michael Weber
  • ASEPTIC PURIFICATION PROCESS FOR VIRUSES
    Publication number: 20200347364
    Abstract: Described herein are processes for the purification of viruses and compositions thereof.
    Type: Application
    Filed: March 11, 2020
    Publication date: November 5, 2020
    Applicant: Valneva SE
    Inventors: Robert Schlegl, Michael Weber
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 10821166
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: November 3, 2020
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 10766931
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 8, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Urban Lundberg, Wolfgang Schüler
  • Zika virus purification
    Patent number: 10744194
    Abstract: Described herein are processes for purifying infectious Zika virus particles and uses of protamine in such processes.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: August 18, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Wruss
  • MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO
    Publication number: 20200239525
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Application
    Filed: December 4, 2019
    Publication date: July 30, 2020
    Applicant: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • VIRUS PURIFICATION
    Publication number: 20200197506
    Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 25, 2020
    Applicant: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccines
    Patent number: 10668146
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 2, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Heindl-Wruss, Michael Weber
  • Virus purification
    Patent number: 10660950
    Abstract: Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: May 26, 2020
    Assignee: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Aseptic purification process for viruses
    Patent number: 10662412
    Abstract: Described herein are processes for the purification of viruses and compositions thereof.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: May 26, 2020
    Assignee: Valneva SE
    Inventors: Robert Schlegl, Michael Weber
  • Zika virus vaccine
    Patent number: 10639365
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: May 5, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • Mutant fragments of OspA and methods and uses relating thereto
    Patent number: 10544194
    Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 28, 2020
    Assignee: Valneva Austria GmbH
    Inventors: Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
  • Virus purification
    Patent number: 10537630
    Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: January 21, 2020
    Assignee: Valneva SE
    Inventors: Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
  • ZIKA VIRUS VACCINE
    Publication number: 20200017555
    Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
    Type: Application
    Filed: December 23, 2016
    Publication date: January 16, 2020
    Applicant: Valneva Austria GmbH
    Inventors: Jana BARBERO CALZADO, Mario NEBENFÜHR, Robert SCHLGEL, Michael WEBER, Jürgen HEINDL-WRUSS